Cardioprotective Effects of Cardiopeptides for Injection in Patients With Non-severe Cardiac Disease: a Single-center Randomized Controlled Trial

• Status: Recruiting
• Trial end date: 2023-11-25
• Target enrollment: 0
• Participant gender: All

Summary

The study was a single-center, randomized controlled trial. To explore the cardioprotective effect of cardiopeptide on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptide was used.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital, Southern Medical University

Criteria

Inclusion Criteria:

1. Age ≥18 years old

2. The high-sensitive troponin T index was higher than the normal value during ICU hospitalization

3. Obtain the informed consent of the subject or legal agent

Exclusion Criteria:

1. Patients who are expected to die within 48 hours of ICU admission

2. previous diagnosis of acute coronary syndrome, chronic cardiomyopathy, pulmonary heart disease, acute myocarditis, pericardial tamponade and other diseases that have been confirmed to cause myocardial injury

3. cardiopulmonary resuscitation and/or electrical defibrillation before admission

4. patients with acute ischemic stroke

5. patients with stage 5 chronic kidney disease

6. during pregnancy or breastfeeding